News about "Merck"

US FDA Approves KEYTRUDA and KEYTRUDA QLEX, Each with Trodelvy

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with Trodelvy as first-line treatment for adults with PD-L1-positive (CPS ≥10) advanced Triple-Negative Breast Cancer (TNBC).

Merck | 26/06/2026 | By News Bureau |  176

Merck Partners with Versant Ventures to Launch Saturnus Bio

Merck has partnered with Versant Ventures to establish Saturnus Bio, advancing precision medicine through gene modulation technologies for rare genetic cardiomyopathies.

Merck | 25/06/2026 | By News Bureau

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Merck | 23/06/2026 | By News Bureau |  301

US FDA Approves Additional Indication for CAPVAXIVE

The US Food and Drug Administration (FDA) has approved an expanded indication for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for children and adolescents aged 2-17 years at increased risk of pneumococcal disease, broadening protection against serious pneumococcal infections in vulnerable pediatric populations.

Merck | 20/06/2026 | By News Bureau |  121

US FDA Approves KEYTRUDA-WELIREG Combination for Adjuvant ccRCC

The US Food and Drug Administration (FDA) has approved KEYTRUDA and KEYTRUDA QLEX in combination with WELIREG for the adjuvant treatment of certain patients with clear cell Renal Cell Carcinoma (ccRCC). The approval expands treatment options for kidney cancer patients at high risk of recurrence following surgery.

Merck | 15/06/2026 | By News Bureau

Gilead and Merck Report Positive Phase 3 Results for Weekly HIV Pill

Gilead and Merck reported positive phase 3 results for the investigational once-weekly oral HIV therapy islatravir/lenacapavir, which has the potential to become the first approved long-acting weekly oral treatment for people living with HIV.

Merck | 09/06/2026 | By News Bureau

US FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC

Calderasib has received US FDA Breakthrough Therapy Designation for certain patients with newly diagnosed metastatic KRAS G12C-mutant Non-Small Cell Lung Cancer (NSCLC), supported by promising phase 1 KANDLELIT-001 trial data highlighting its potential as a next-generation, highly potent and selective KRAS G12C inhibitor.

Merck | 30/05/2026 | By News Bureau |  105

Merck Doses First Patient in Phase 3 Trial of Investigational ADC for Colorectal Cancer

Merck announces first patient dosing in a phase 3 trial evaluating investigational Antibody Drug Conjugate (ADC) precemtabart tocentecan for metastatic colorectal cancer, targeting CEACAM5 expressed in most colorectal tumors.

Merck | 22/05/2026 | By News Bureau |  122

Merck's Phase 3 TroFuse-005 Trial Shows Survival Benefit of Sac-TMT in Advanced Endometrial Cancer

Merck announced that its phase 3 TroFuse-005 trial evaluating investigational antibody-drug conjugate Sacituzumab Tirumotecan (sac-TMT) met primary endpoints of overall survival and progression-free survival in patients with advanced or recurrent endometrial cancer.

Merck | 19/05/2026 | By News Bureau |  117

Merck Becomes Sole Testing Provider for FDA-Approved Gene Therapies of Genetix Biotherapeutics

Merck signs a 5-year deal as sole testing provider for Genetix Biotherapeutics’ gene therapies, delivering end-to-end testing to support safe, reliable commercialisation of advanced therapies.

Merck | 08/05/2026 | By News Bureau |  120